[California] Carelon Medical Benefits Management Clinical Appropriateness Guidelines updates
Effective for dates of service on and after November 15, 2026, updated Carelon Medical Benefits Management Clinical Appropriateness Guidelines apply to Medicare Advantage. Genetic and somatic tumor testing requires that all components of a test demonstrate clinical utility, and whole exome, whole genome and whole transcriptome analysis are considered not medically necessary. Joint procedures now require 12 weeks of conservative management with a shorter allowance for severe impact on daily activities, arthroscopy is excluded for Kellgren-Lawrence grade 4 osteoarthritis, and bilateral hypoglossal nerve stimulators are excluded for obstructive sleep apnea.